Skip to main content
SpringerLink
Log in

Palliative care in poor-performance status small cell lung cancer patients: is there a mandatory role for chemotherapy?

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

Small cell lung cancer (SCLC) is an aggressive malignancy but with a high response rate to chemotherapy. Eastern Cooperative Oncology Group performance status (ECOG PS) has been recognized as one of the main prognostic factors in SCLC. There are few data about risk–benefit ratio of chemotherapy over exclusive best supportive care in ECOG PS 3 and 4 patients. This study was performed to assess the outcome of poor ECOG PS SCLC patients that received chemotherapy in our institution.

Methods

A retrospective review of medical records from patients with ECOG PS 3–4 SCLC, who received systemic chemotherapy, was performed between January 2001 and December 2006 at the Instituto Nacional do Câncer, Rio de Janeiro, Brazil.

Results

A total of 40 patients were included. Extensive disease was observed in 85% of patients and 25% had PS 4. The median overall survival was 53 days (64 days for ECOG PS 3 and 7 days for ECOG PS 4). There were 30% of early deaths. On univariate analysis, lactate dehydrogenase value, need for hospital admission, and exposure to radiotherapy had impact on survival. ECOG PS 3 patients had better survival than PS 4 patients, even when adjusted for stage. On multivariate analysis, ECOG PS, combined with stage, sustained a major influence on survival.

Conclusions

Median survival for ECOG PS 4 patients treated with chemotherapy in our series was extremely short with a high rate of early deaths. ECOG PS 3 patients also showed a poor survival. These data suggest that we need a more comprehensive approach and further studies, regarding the palliative care of this high-risk population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Parkin DM, Pisani P, Ferlay J (1999) Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80:827–841

    Article  PubMed  CAS  Google Scholar 

  2. Chua YJ, Steer C, Yip D (2004) Recents advances in management of small-cell lung cancer. Cancer Treat Rev 30:521–543

    Article  PubMed  CAS  Google Scholar 

  3. Ihde DC (1992) Chemotherapy of lung cancer. N Engl J Med 327:1434–1441

    Article  PubMed  CAS  Google Scholar 

  4. Lassen UN, Østerlind K, Hirsch FR, Bergman B, Dombernowsky P, Hansen HH (1999) Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression. Br J Cancer 79:515–519

    Article  PubMed  CAS  Google Scholar 

  5. Quoix E, Hedelin G, Popin E, Charloux A, Dietemann A, Seibert R et al (1993) Can we predict very short long term survival in small cell lung cancer? Lung Cancer 10:229–238

    Article  PubMed  CAS  Google Scholar 

  6. Bremnes RM, Sundstrom S, AasebØ U, Kaasa S, Hatlevoll R, Aamdal S et al (2003) The value of prognostic factors in small cell lung cancer: results from a randomized multicenter study with minimum 5-year follow-up. Lung Cancer 39:303–313

    Article  PubMed  Google Scholar 

  7. Yip D, Harper P (2000) Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer 28:173–185

    Article  PubMed  CAS  Google Scholar 

  8. Paesmans M, Sculier JP, Lecomte J, Thiriaux J, Libert P, Sergysels R et al (2000) Prognostic factors for patients with small cell lung cancer carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 89:523–533

    Article  PubMed  CAS  Google Scholar 

  9. Hauser CA, Stockler MR, Tattersall MHN (2006) Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review. Support Care Cancer 14:999–1011

    Article  PubMed  Google Scholar 

  10. Karnofsky DA, Abelmann WH, Craver LF et al (1948) The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma Cancer 1:634–656

    Google Scholar 

  11. Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655

    Article  PubMed  CAS  Google Scholar 

  12. Taylor AE, Olver IN, Sivanthan T et al (1999) Observer error in grading performance status in cancer patients. Support Care Cancer 7:332–335

    Article  PubMed  CAS  Google Scholar 

  13. Albain KS, Crowley JJ, LeBlanc M et al (1990) Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group database. J Clin Oncol 8:1563–1574

    PubMed  CAS  Google Scholar 

  14. Buccheri G, Ferrigno D (1994) Prognostic factors in lung cancer: tables and comments. Eur Respir J 7:1350–1364

    Article  PubMed  CAS  Google Scholar 

  15. Paesmans M, Sculier JP, Lecomte J et al (2000) Prognostic factors for patients with small cell lung carcinoma. Cancer 89:523–533

    Article  PubMed  CAS  Google Scholar 

  16. van Meerbeeck JP, Fennell DA, De Ruysscher DKM (2011) Small-cell lung cancer. The Lancet DOI:. doi:10.1016/S0140-6736(11)60165-7

  17. Sakuragi T, Oshita F, Nagashima S, Kasai T, Kurata T, Fukuda M et al (1996) Retrospective analysis of the treatment of patients with small cell lung cancer showing poor performance status. Jpn J Clin Oncol 26:128–133

    Article  PubMed  CAS  Google Scholar 

  18. Kenmotsu H, Goto K, Kubota K, Ohmatsu H, Niho S Yoh K, et al. (2008) Clinical significance of chemotherapy for small cell lung cancer (SCLC) with ECOG performance status (PS) 3–4. J Clin Oncol 26 s: abstr 19123.

  19. Barbera L, Paszat L, Qiu F (2008) End-of-life in lung cancer patients in Ontario: aggressiveness of care in the population and a description of hospital admissions. J Pain Symptom Manag 35:267–274

    Article  Google Scholar 

  20. Alvarez MP, Rubio OG, Cosp XB, Varela YA (2009) Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev (4):CD001990.

  21. Lassen UN, Østerlind K, Hansen M, Dombernowsky P, Bergman B, Hansen HH (1995) Long-term survival in small-cell lung cancer: post treatment characteristics in patients surviving 5 to 18+ years—an analysis of 1,714 consecutive patients. J Clin Oncol 13(5):1215–1220

    PubMed  CAS  Google Scholar 

  22. Rawson NSB, Peto J (1990) An overview of prognostic factors in small cell lung cancer: a report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer 61:597–604

    Article  PubMed  CAS  Google Scholar 

  23. Maestu I, Pastor M, Gomez-Codina J, Aparicio J, Oltra A, Herranz C et al (1997) Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic índex and validation of three known prognostic indices on 341 patients. Ann Oncol 8:547–553

    Article  PubMed  CAS  Google Scholar 

  24. Okamoto H, Watanabe K, Kunikane H, Yokoyama A, Kudoh S, Asakawa T et al (2007) Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 97:162–169

    Article  PubMed  CAS  Google Scholar 

  25. Lilenbaun RC, Huber RM, Treat J, Masters G, Kaubitzsch S, Lane S et al (2006) Topotecan therapy in patients with relapsed small-cell lung cancer and poor performance status. Clin Lung Cancer 8:130–134

    Article  Google Scholar 

  26. Mackay HJ, O’Brien M, Hill S, Lees SM, Thatcher N, Smith IE et al (2003) A phase II study of carboplatin and vinorelbine in patients with poor prognosis small cell lung cancer. Clin Oncol 15:181–185

    Article  CAS  Google Scholar 

  27. Garassino MC, Torri V, Michetti G et al (2010) Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. Lung Cancer. doi:10.1016/j.lungcan.2010.09.009

  28. Morris J, Woolnough K, Sheldon J, Nanda U, Beckett P (2009) An audit of SCLC patients not receiving chemotherapy. Lung Cancer 63:S10

    Article  Google Scholar 

  29. Koedoot CG, De Haes JC, Heisterkamp SH et al (2002) Palliative chemotherapy or watchful waiting? A vignettes study among oncologists. J Clin Oncol 20:3658–3664

    Article  PubMed  CAS  Google Scholar 

  30. Winter MC, Potter VA, Woll PJ (2008) Raised serum urea predicts for early death in small cell lung cancer. Clin Oncol 20:745–750

    Article  CAS  Google Scholar 

  31. Østerlind K, Andersen PK (1986) Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 46:4189–4194

    PubMed  Google Scholar 

  32. Radford JA, Ryder WDJ, Dodwell D (1993) Predicting septic complications of chemotherapy: an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis. Eur J Cancer 29A:81–86

    Article  Google Scholar 

  33. McNiff KK, Neuss MN, Jacobson JO et al (2008) Measuring supportive care in medical oncology practice: Lessons learned from the quality oncology practice initiative. J Clin Oncol 26:3832–3837

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

The authors have no conflict of interest. This study is supported by department funding only. The authors have full control of all primary data and agree to allow the journal to review their data if requested.

Author information

Authors and Affiliations

  1. Division of Clinical Oncology, Instituto Nacional do Câncer (INCA), Rua André Cavalcanti, 32, Centro Rio de Janeiro, Rio de Janeiro, 20231-050, Brazil

    Clarissa Seródio Baldotto & Mauro Zukin

  2. Department of Clinical Research, Centro Regional Integrado de Oncologia (CRIO), Fortaleza, Ceará, Brazil

    Eduardo Henrique Cronemberger

  3. Department of Thoracic Surgery, Instituto Nacional do Câncer (INCA), Rio de Janeiro, Rio de Janeiro, Brazil

    Paulo de Biasi, Mauro Zamboni & Aureliano Sousa

  4. Coordination of Clinical and Translational Research, Instituto Nacional do Câncer (INCA), Rio de Janeiro, Rio de Janeiro, Brazil

    Isabelle A. Small & Carlos Gil Ferreira

Authors
  1. Clarissa Seródio Baldotto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eduardo Henrique Cronemberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paulo de Biasi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mauro Zamboni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Aureliano Sousa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mauro Zukin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Isabelle A. Small
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Carlos Gil Ferreira
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Clarissa Seródio Baldotto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baldotto, C.S., Cronemberger, E.H., de Biasi, P. et al. Palliative care in poor-performance status small cell lung cancer patients: is there a mandatory role for chemotherapy?. Support Care Cancer 20, 2721–2727 (2012). https://doi.org/10.1007/s00520-012-1392-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-012-1392-0

Keywords

Search

Navigation